Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders

Area of Science:

• Biochemistry
• Pharmacology
• Pulmonary Medicine

Background:

• Transforming growth factor β (TGFβ) pathway dysregulation is linked to chronic lung disorders, including asthma, COPD, interstitial pneumonias, and pulmonary arterial hypertension (PAH).
• Pharmaceutical efforts to inhibit the TGFβ pathway via type I/II receptors or ligands have yielded slow progress.
• Dose-limiting safety issues arise from antagonizing the TGFβ pathway, essential for immune surveillance and cardiovascular regulation.

Purpose of the Study:

• To review the rationale and limitations of TGFβ pathway inhibitors in chronic lung disorders.
• To explore targeting TGFβ superfamily ligand accessory proteins as an alternative therapeutic strategy.

Main Methods:

• Literature review of existing research on TGFβ pathway inhibitors and their application in chronic lung diseases.
• Analysis of the potential of targeting TGFβ superfamily ligand accessory proteins for therapeutic modulation.

Main Results:

• Conventional TGFβ pathway inhibition presents significant safety challenges, hindering therapeutic development for chronic lung conditions.
• Targeting accessory proteins offers a potential strategy for rheostatic regulation of TGFβ signaling.
• This approach may allow for improved efficacy while maintaining a sufficient therapeutic index.

Conclusions:

• Conventional TGFβ pathway inhibitors face substantial safety hurdles for treating chronic lung disorders.
• Targeting TGFβ superfamily ligand accessory proteins represents a promising alternative for achieving therapeutic efficacy with an improved safety profile.
• Further research into accessory protein modulation is warranted for developing safer treatments for conditions like asthma and COPD.